Study Population
Tumors
TUMORS, DISEASE, ONCOLOGY
Both phases of the study enrolled adult patients (aged ≥18 years) with histologically or cytologically confirmed mCRC, evidence of measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), Eastern Cooperative Oncology Group performance status of 0 to 2, and written documentation of either For phase Ib, eligible patients had mCRC that had progressed on or following standard therapy or were determined to be patients for whom no standard therapy existed. For phase II, patients were eligible based on their previous anti-EGFR mAb therapy and 